Stay updated with breaking news from Yescarta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Over the last ten years, we have witnessed a transformation from speculative science to a reality where genetic disorders are treated not just in theory but in reality. ....
Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial. ....
Santa Monica: Kite Pharma, Inc., a Gilead Company, has announced that the Marketing Authorization in Japan for Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has. ....
A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL). ....